Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils
Molecular Pharmaceutics · 05.01.2026 · 23 (1) · 164-176
DOI: 10.1021/acs.molpharmaceut.5c00578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.12.2025. Verfasst von Xinyang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge CB2 1EW, U.K. Hauptthemen laut MEDLINE: Amyloid, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.
Abstract (Originalsprache)
Teverelix is a short non-natural peptide, which is a gonadotropin releasing hormone antagonist and used as a treatment for prostate cancer. Teverelix is formulated as a trifluoroacetic acid salt, which, at the high concentrations used for parenteral injection, forms a microcrystalline suspension. At low concentrations and immediately after injection, teverelix self-assembles into a fibrillar species thought to be important for the slow-release kinetics and long-acting action of this peptide in vivo. In this paper, we confirmed the amyloid-like identity of teverelix fibrils using X-ray fiber diffraction and transmission electron microscopy. The inter-β-sheet packing distance was found to be larger than that of typical amyloid fibrils and this was attributed to the large non-natural side chains within the peptide. Using data from numerous biophysical experiments, a model of the structure of teverelix within the fibril is proposed. The kinetics of fibril formation were investigated using standard ThT assays, and teverelix found to fibrillate rapidly over a wide range of conditions. The fibrillation rate was shown to depend critically upon pH, peptide, and trifluoroacetic acid concentration. Fibrillation was accompanied by a drop in pH, which we attribute to the fact that the pyridinium side chain must be deprotonated before self-assembly. Based on our results, we propose a nucleation-polymerization mechanism in which dimers of teverelix rapidly self-assemble into amyloid-like fibrils with little change in the secondary structure but burial of some of the aromatic acid side chains. Interestingly, the fibrils can, under certain conditions, align to create a highly ordered array. To the best of our knowledge, this is the first paper studying teverelix in detail from a biophysical perspective, and it is directly relevant to the aggregation of the peptide observed in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge CB2 1EW, U.K.
- Sussex Neuroscience, School of Life Sciences, University of Sussex, Brighton BN1 9QG, U.K.
- CMCAssist ApS, Ole Maalo̷es Vej 3, Copenhagen N 2200, Denmark.
- Boutignon & Partners, 2 rue Michel Renaud, Biopole Clermont-Limagne, Saint Beauzire 63360, France.
- Antev Ltd, Ibex House, Baker Street, Weybridge, Surrey KT13 8AH, U.K.
ORCID-Profile: Louise C Serpell, Sophie E Jackson
Förderung
- China Scholarship Council
Zitieren
APA
Li, X., Serpell, L. C., Bukrinski, J. T., Boutignon, F., MacLean, C. M., & Jackson, S. E. (2026). Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils. Molecular Pharmaceutics, 23(1), 164-176. https://doi.org/10.1021/acs.molpharmaceut.5c00578
Vancouver
Li X, Serpell LC, Bukrinski JT, Boutignon F, MacLean CM, Jackson SE. Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils. Molecular Pharmaceutics. 2026;23(1):164-176. doi:10.1021/acs.molpharmaceut.5c00578
BibTeX
@article{Li2026,
author = {Li, Xinyang and Serpell, Louise C and Bukrinski, Jens T and Boutignon, Francois and MacLean, Carol M and Jackson, Sophie E},
title = {Mechanism of Self-Assembly of the Gonadropin Releasing Hormone Antagonist Teverelix into Amyloid Fibrils},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {1},
pages = {164--176},
doi = {10.1021/acs.molpharmaceut.5c00578}
}
EUVIMED